Viatris launches Inpefa in UAE after January approval, begins first commercial rollout outside core markets
Key Facts
Viatris announced on January 20, 2026, the launch of Inpefa, known scientifically as sotagliflozin, in the UAE, making the country the first market in the company's regions to introduce the treatment commercially. The Emirates Drug Establishment had announced its approval on January 12, describing the UAE at the time as the second country in the world to approve the drug. The launch allows the company to begin marketing the treatment in a market outside the United States and Europe, as part of a plan it said aims to expand access in key markets. The approval covers adults with heart failure, as well as patients with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. The treatment aims to reduce the risks of cardiovascular death, hospitalization for heart failure and urgent visits related to it.
Viatris described the drug as the first dual SGLT1 and SGLT2 inhibitor approved to treat heart failure. The approval is based on the phase 3 SOLOIST-WHF and SCORED trials, which together included more than 11,800 patients worldwide. In the SOLOIST-WHF trial, which included patients recently hospitalized for worsening heart failure, the company said the treatment reduced by 33% the composite risk of hospitalization for heart failure, urgent visits or cardiovascular death compared with placebo. SCORED studied patients with type 2 diabetes, chronic kidney disease and cardiovascular risk factors, whether or not they had heart failure. Viatris said the treatment achieved a 25% reduction in the same composite outcome in that trial.
U.S. Food and Drug Administration data provide additional detail on the SOLOIST result: the rate of the composite outcome was 51.3 events per 100 patient-years with Inpefa, compared with 76.4 with placebo. The hazard ratio was 0.67, with a p-value of 0.001. The SCORED trial enrolled 10,584 patients, and the agency reported a statistically significant reduction in the risk of the composite outcome in the studied population. The agency says the drug's original U.S. approval was issued on May 26, 2023, based on evidence from two trials with a total of 11,806 participants. This places the UAE launch within a regulatory path that began in the United States before the treatment's commercial rollout in the first of Viatris's markets outside the United States and Europe.
The commercial framework for the launch dates to an exclusive licensing agreement Viatris announced with Lexicon Pharmaceuticals in October 2024 to market sotagliflozin in all markets outside the United States and Europe. Lexicon markets Inpefa in the United States, according to a Viatris statement. The agreement places the UAE within the markets where Viatris manages marketing of the treatment, while the company said launches in other countries are planned over the following years. That makes the expected geographic expansion part of a strategy to make the drug available in new markets, without the statement specifying a date for any particular country. The announcement also did not link the launch to revenue expectations, describing it instead as a step to expand access to treatment in key markets outside the United States and Europe.
In trading on November 18, 2026, Viatris shares, listed under the ticker VTRS, closed at $20.28, according to EL7 data. The price comes as the market monitors the company after it announced in November a third-quarter net loss and raised the midpoints of its 2026 guidance, according to the related news headline. However, the closing data cited here do not identify the stock's movement in response to the Inpefa launch, which was announced in January. The announced commercial step remains part of the company's expansion of its innovative portfolio outside the United States and Europe, while Viatris did not specify dates for the next markets in its launch statement. The company said multiple launches in other countries are planned over the following years.